Your browser doesn't support javascript.
loading
CD38high/HLA-DR+CD8+ T lymphocytes display pathogen-specific expansion regardless of hemophagocytic lymphohistiocytosis.
Lodi, Lorenzo; Sarli, Walter Maria; Ricci, Silvia; Pisano, Laura; Boscia, Silvia; Mastrolia, Maria Vincenza; Malinconi, Sara; Fusco, Eleonora; Sieni, Elena; Indolfi, Giuseppe; Simonini, Gabriele; Galli, Luisa; Azzari, Chiara.
Afiliación
  • Lodi L; Department of Health Sciences, University of Florence, Florence, Italy.
  • Sarli WM; Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Ricci S; Department of Health Sciences, University of Florence, Florence, Italy.
  • Pisano L; Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Boscia S; Department of Health Sciences, University of Florence, Florence, Italy.
  • Mastrolia MV; Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Malinconi S; Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Fusco E; Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Sieni E; Rheumatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Indolfi G; Department of Health Sciences, University of Florence, Florence, Italy.
  • Simonini G; Department of Health Sciences, University of Florence, Florence, Italy.
  • Galli L; Pediatric Hematology-Oncology Department, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Azzari C; Hepatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Eur J Immunol ; : e2451140, 2024 Sep 03.
Article en En | MEDLINE | ID: mdl-39226525
ABSTRACT
The characteristic expansion of T CD38high/HLA-DR+CD8+ lymphocytes observed in hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) proved able to distinguish HLH/MAS from sepsis and systemic juvenile idiopathic arthritis. However, the performance of this marker in differentiating HLH/MAS from other pediatric febrile conditions with similar clinical onset and yet entirely different treatments remains unexplored. CD38high/HLA-DR+CD8+ frequencies measured in the peripheral fresh blood of pediatric patients attended for suspicion of HLH/MAS were retrospectively recorded and clinical characteristics were retrieved. CD38high/HLA-DR+CD8+ frequencies in HLH/MAS patients (15 patients; median 22.0%, IQR 11.0-49.0%) were compared with those who presented febrile conditions other-than-HLH (28 patients; median 13.0%, IQR 3.9-28.7%; p = 0.24). HLH and non-HLH patients were subsequently regrouped based on the presence of an identified infection (22 patients; median 27.0%, IQR 15.2-72.1%) and compared with those without infections (21 patients; median 7.6%, IQR 3.7-24.3%; p = 0.0035). CD38high/HLA-DR+CD8+ percentages were significantly higher only in the infection group compared with the noninfection one, with a patent pathogen-specific expansion in Epstein-Barr virus primoinfection and visceral leishmaniasis regardless of the presence of HLH. CD38high/HLA-DR+CD8+ frequencies do not appear as an HLH-specific marker as they naturally expand in other clinical situations that are common in childhood and may mimic HLH initial presentation.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Eur J Immunol Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Eur J Immunol Año: 2024 Tipo del documento: Article País de afiliación: Italia